HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A high ratio of apoptosis to proliferation correlates with improved survival after radiotherapy for cervical adenocarcinoma.

AbstractPURPOSE:
A retrospective study was made of the role of apoptosis in determining radiotherapy outcome in 39 adenocarcinoma of the cervix. A comparison was also made of the detection of apoptosis by morphology and the TdT dUtp nick end-labeling (TUNEL) assay.
METHODS AND MATERIALS:
The level of apoptosis was assessed in paraffin-embedded sections by cell morphology, the TUNEL assay, and a combination of the two. A total of 2,000 cells were counted per section, to obtain apoptotic (AI) and mitotic (MI) indices.
RESULTS:
Patients with a high AI had a higher survival rate than those with a low AI, however, the difference was not significant. Using a ratio of apoptosis to proliferation indices, patients with an AI:MI > median had significantly better survival than those with AI:MI < median. This was true where the AI was quantified by morphology alone (p = 0.030) or in combination with the TUNEL assay (p = 0.008). Where the AI was quantified by a combination of morphology and TUNEL, the 5-year survival rates for women with AI:MI greater or less than the median were 81% and 25%, respectively.
CONCLUSION:
A high ratio of AI:MI in adenocarcinoma of the cervix indicates a good prognosis. A combination of the TUNEL assay and morphology provided the best discrimination between outcome groups.
AuthorsM T Sheridan, R A Cooper, C M West
JournalInternational journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 44 Issue 3 Pg. 507-12 (Jun 01 1999) ISSN: 0360-3016 [Print] United States
PMID10348278 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Adenocarcinoma (mortality, pathology, radiotherapy)
  • Adult
  • Aged
  • Aged, 80 and over
  • Apoptosis
  • Cell Division
  • Female
  • Humans
  • In Situ Nick-End Labeling (methods)
  • Middle Aged
  • Mitotic Index
  • Prognosis
  • Reproducibility of Results
  • Uterine Cervical Neoplasms (mortality, pathology, radiotherapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: